Willkommen, schön sind Sie da!
Logo Ex Libris

Progress in Drug Research

  • Kartonierter Einband
  • 340 Seiten
(0) Erste Bewertung abgeben
Bewertungen
(0)
(0)
(0)
(0)
(0)
Alle Bewertungen ansehen
Due tothedevelopmentofdrugresistanceandotherlimitationsinthe treat ment of AIDS patients with reverse transcriptase (RT) inhibitor... Weiterlesen
CHF 115.00
Print on Demand - Auslieferung erfolgt in der Regel innert 4 bis 6 Wochen.
Bestellung & Lieferung in eine Filiale möglich

Beschreibung

Due tothedevelopmentofdrugresistanceandotherlimitationsinthe treat ment of AIDS patients with reverse transcriptase (RT) inhibitors like zidovu dineandothers, itbecamenecessarytoexploreantiviralagentsactingontar getsotherthan RT. Inthepastfewyears, hundredsofHIVproteaseinhibitoLs have been synthesized and tested. Among these protease inhibitors, saquinavir, ritonavir, indinavir and nelfinavir have been marketed during 1995-1997. In this review, emphasis is placed on the development of HIV protease inhibitors as antiviral agents against HIV, structure-activity rela tionship (SAR) analysis ofsaquinavirand relatedcompounds, comparisonof four marketed HIV protease inhibitors, and future prospect in developing new anti-HIV drugs. 2 Introduction HIV protease inhibitors 3 HIV protease as a target for chemotherapy HIV protease was first suggested as a potential target for AIDS therapy by Kramer et a1. in 1986 [5]. HIV protease is a proteolytic enzyme responsible for cleaving large numbers of amino acid sequences. This enzyme regulates conversionoftheselargeaminoacid sequencesintobiologicallyactive struc tural and functional protein products. Specifically, HIV protease is responsi the enzymatic processing of the gagand gag-pol genes of HIV, which ble for encode for functional core proteins and viral enzymes (reverse transcriptase, ribonuclease H, integrase, and HIV protease). The polyproteins encoded by the gagand gag-pol genes undergo post-translational processing by HIV pro tease to form functional protein products as the viral particles budding out from infected cells. Therefore, inhibition of HIV protease by a protease inhibitor results in the release ofimmature, noninfectious viral particles [4].

Klappentext

Due tothedevelopmentofdrugresistanceandotherlimitationsinthe treat­ ment of AIDS patients with reverse transcriptase (RT) inhibitors like zidovu­ dineandothers, itbecamenecessarytoexploreantiviralagentsactingontar­ getsotherthan RT. Inthepastfewyears, hundredsofHIVproteaseinhibitoLs have been synthesized and tested. Among these protease inhibitors, saquinavir, ritonavir, indinavir and nelfinavir have been marketed during 1995-1997. In this review, emphasis is placed on the development of HIV protease inhibitors as antiviral agents against HIV, structure-activity rela­ tionship (SAR) analysis ofsaquinavirand relatedcompounds, comparisonof four marketed HIV protease inhibitors, and future prospect in developing new anti-HIV drugs. 2 Introduction HIV protease inhibitors 3 HIV protease as a target for chemotherapy HIV protease was first suggested as a potential target for AIDS therapy by Kramer et a1. in 1986 [5]. HIV protease is a proteolytic enzyme responsible for cleaving large numbers of amino acid sequences. This enzyme regulates conversionoftheselargeaminoacid sequencesintobiologicallyactive struc­ tural and functional protein products. Specifically, HIV protease is responsi­ the enzymatic processing of the gagand gag-pol genes of HIV, which ble for encode for functional core proteins and viral enzymes (reverse transcriptase, ribonuclease H, integrase, and HIV protease). The polyproteins encoded by the gagand gag-pol genes undergo post-translational processing by HIV pro­ tease to form functional protein products as the viral particles budding out from infected cells. Therefore, inhibition of HIV protease by a protease inhibitor results in the release ofimmature, noninfectious viral particles [4].



Inhalt

Development of HIV protease inhibitors: A survey.- Insulin resistance, impaired glucose tolerance and non-insulin-dependent diabetes, pathologic mechanisms and treatment: Current status and therapeutic possibilities.- Peptide drug delivery into the central nervous system.- Abnormalities of protein kinases in neurodegenerative diseases.- Biomimicry as a basis for drug discovery.- Serotonin in migraine: Theories, animal models and emerging therapies.- The application of high-throughput screening to novel lead discovery.- Index Vol. 51.- Index of titles, Vol. 1-51.- Author and paper index, Vol. 1-51.

Produktinformationen

Titel: Progress in Drug Research
Autor:
EAN: 9783034897983
ISBN: 3034897987
Format: Kartonierter Einband
Herausgeber: Birkhäuser Basel
Genre: Medizin
Anzahl Seiten: 340
Gewicht: 578g
Größe: H240mm x B170mm x T18mm
Jahr: 2011
Auflage: Softcover reprint of the original 1st ed. 1998

Weitere Produkte aus der Reihe "Progress in Drug Research"